Pre-Open Stock Movers 8/16: (STEM) (ANTH) (EBIO) Higher; (OGXI) (HAIN) (HTBX) Lower
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) 34.3% LOWER; announced results from the final analysis of AFFINITY, the Phase 3 trial of custirsen in men with metastatic castrate-resistant prostate cancer (CRPC) whose disease has progressed after treatment with docetaxel. The trial did not meet the primary endpoint of demonstrating a statistically significant improvement in overall survival for patients treated with custirsen in combination with cabazitaxel/prednisone compared to cabazitaxel/prednisone alone.
The Hain Celestial Group, Inc. (Nasdaq: HAIN) 26.3% LOWER; announced that it will delay the release of its fourth quarter and fiscal year 2016 financial results. During the fourth quarter, the Company identified concessions that were granted to certain distributors in the United States. The Company is currently evaluating whether the revenue associated with those concessions was accounted for in the correct period and is also currently evaluating its internal control over financial reporting.
StemCells (Nasdaq: STEM) 20.9% HIGHER; enters merger with Microbot Medical.
Heat Biologics (Nasdaq: HTBX) 14.8% LOWER; On August 15, 2016, Heat Biologics, Inc. (the “Company”) and FBR Capital Markets & Co. (“FBR”) entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) pursuant to which the Company may sell from time to time, at its option, shares of its common stock, par value $0.0002 per share, having an aggregate offering price of up to $10,500,000 through FBR, as sales agent.
Evoke Pharma (Nasdaq: EVOK) 9.2% LOWER; reported Q2 EPS of ($0.41), $0.02 better than the analyst estimate of ($0.43). As of June 30, 2016, the Company's cash and cash equivalents were approximately $4.1 million.
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) 8.5% HIGHER; announced that the Data and Safety Monitoring Board (DSMB) completed its first pre-planned safety review of the Phase 3 SOLUTION clinical study of Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency. The DSMB had “no concerns regarding safety of the data to date, and voted that the study continue without modification to the protocol or charter.”
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO) 8.4% HIGHER; announced the effectiveness of the exclusive licensing deal with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche). Eleven has granted Roche an exclusive, worldwide license to develop and commercialize EBI-031 and all other IL-6 antagonist antibody technology owned by Eleven.
Allot Communications Ltd. (Nasdaq: ALLT) 8.1% HIGHER; Soros reports passive 6.61 percent stake.
Dick's Sporting Goods (NYSE: DKS) 7.9% HIGHER; reported Q2 EPS of $0.82, $0.13 better than the analyst estimate of $0.69. Revenue for the quarter came in at $2 billion versus the consensus estimate of $1.88 billion. Comps rose 2.8%. Sees Q3 EPS of $0.39 - $0.42 and comps up 2 - 3 percent. The Street sees Q3 EPS of $0.38.
Alarm.com Holdings, Inc. (Nasdaq: ALRM) 7.2% LOWER; reported Q2 EPS of $0.15, $0.04 better than the analyst estimate of $0.11. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $58.61 million. Alarm.com Holdings, Inc. sees FY2016 EPS of $0.49-$0.51, versus the consensus of $0.48. Alarm.com Holdings, Inc. sees FY2016 revenue of $242.3-245.8 million, versus the consensus of $241.67 million.
Vipshop Holdings (NYSE: VIPS) 7.1% HIGHER; reported Q2 EPS of $0.17, $0.02 better than the analyst estimate of $0.15. Revenue for the quarter came in at $2.02 billion versus the consensus estimate of $1.9 billion.
Momo (Nasdaq: MOMO) 7.0% HIGHER; reported Q1 EPS of $0.12, $0.04 better than the analyst estimate of $0.08. Revenue for the quarter came in at $99 million, versus $30.7 million reported last year.
Fabrinet (NYSE: FN) 6.2% HIGHER; reported Q4 EPS of $0.60, in-line with the analyst estimate of $0.60. Revenue for the quarter came in at $276.4 million versus the consensus estimate of $262.95 million. Fabrinet sees Q1 2017 EPS of $0.70-$0.72, versus the consensus of $0.60. Fabrinet sees Q1 2017 revenue of $306-310 million, versus the consensus of $269.5 million.
Univar Inc. (NYSE: UNVR) 6.1% LOWER; announced the pricing of the previously announced public offering of 20,943,741 shares of Univar's common stock (representing approximately 15.2% of its issued and outstanding shares) by Univar N.V. and GSO COF Facility LLC (the "Selling Stockholders") to Goldman, Sachs & Co., as the sole underwriter in the registered public offering of those shares, at a price to the public of $19.00 per share.
Praxair (NYSE: PX) 4.9% HIGHER; Praxair and Germany's Linde have held talks to merger, according to Bloomberg, citing people familiar with the matter. The status of talks isn't clear, and a potential deal could attract scrutiny from antitrust regulators, though the two sides may move to conduct divestitures aimed at quelling regulatory concerns.
Spark Therapeutics (Nasdaq: ONCE) 4.4% LOWER; ONCE holder Children's Hospital of Philadelphia offered 1 million shares at $61.30-$61.9
Hospitality Properties Trust (Nasdaq: HPT) 4.3% LOWER; announced that it has priced a public offering of 11,000,000 common shares at a price to the public of $30.75 per common share.
Aratana Therapeutics, Inc. (Nasdaq: PETX) 4.1% HIGHER; announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved NOCITA® (bupivacaine liposome injectable suspension) as a local post-operative analgesia for cranial cruciate ligament surgery in dogs. Aratana anticipates Nocita will be commercially available to veterinarians in the fall of 2016.
Concho Resources Inc. (NYSE: CXO) 3.7% LOWER; announced that it has priced a public offering of 9,000,000 shares of its common stock for total gross proceeds (before underwriters’ fees and estimated expenses) of approximately $1,178 million.
Autohome (NYSE: ATHM) 3.2% HIGHER; reported Q2 EPS of $0.46, $0.06 better than the analyst estimate of $0.40. Revenue for the quarter came in at $207.4 million versus the consensus estimate of $207.38 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moody's Lowers Outlook on Zayo Group (ZAYO) to Stable; Ratings Affirmed
- Trading Radar for 12/5: GW Pharma (GWPH), KongZhong (KZ) Report